|Over a month ago|
Corvus recent rally due to AstraZeneca data, says Roth Capital » 10:4109/2209/22/21
Roth Capital analyst Tony…
Roth Capital analyst Tony Butler keeps a Buy rating on Corvus Pharmaceuticals (CRVS) with a $6 price target after the company published an update on its Covid-19 trial for anti-CD73 antibody mupadolimab. This trial is no longer ongoing, yet a Phase I trial with mupadolimab in combination with adenosine A2a receptor antagonist ciforadenant and pembrolizumab against solid tumors continues, Butler tells investors in a research note. The analyst says the recent run Corvus shares is not the result of any data directly related to mupadolimab, however. Rather, the rally is due to lateral competitor AstraZeneca (AZN) presenting data on its anti-CD73 in combination with anti-PD-L1 antibody durvalumab, says Butler. Shares of Corvus Pharmaceuticals are down 4% to $8.21 in morning trading. The analyst notes that mupadolimab currently is in Phase I clinical study for advanced cancers including non-small cell lung, ovarian, bladder, prostate, renal cell carcinoma, colorectal cancer, triplenegative breast, cervical, sarcoma, head and neck and non-Hodgkin's lymphoma.
Unusually active option classes on open September 22nd » 09:4009/2209/22/21
MIC, SOFI, LEN, CRVS, LCID, HSBC, MOS, BTU, BP
Unusual total active…
Unusual total active option classes on open include: Macquarie Infrastructure (MIC), Direxion Daily China Bear 3X Shares (YANG), SoFi Technologies (SOFI), Lennar (LEN), Corvus Pharmaceuticals (CRVS), Lucid Group (LCID), HSBC (HSBC), Mosaic (MOS), Peabody Energy (BTU), and BP (BP).
Corvus Pharmaceuticals provides update on mupadolimab in viruses and tumors » 06:0409/2209/22/21
Corvus Pharmaceuticals provided an update on its development programs in oncology and infectious disease for mupadolimab. Corvus is developing mupadolimab as a therapeutic for oncology indications and for infectious disease, starting with COVID-19. Results from its Phase 3 clinical trial of mupadolimab for COVID-19, which cover 40 patients enrolled in the trial prior to its voluntary discontinuation, suggest improvement in the primary and key secondary endpoints in patients treated with single doses of mupadolimab at 2mg/kg and 1mg/kg compared to placebo. No drug related adverse events were reported in the trial. The company believe there is mounting evidence that mupadolimab could become a universal treatment for viral diseases, with the ability to address immune escape from variants. The company plans to evaluate next steps with mupadolimab for COVID-19 as it explores partnership opportunities to continue its development as a therapeutic. Mupadolimab also is currently being studied in a Phase 1b/2 clinical study in patients with HPV+ oropharyngeal cancers and non small cell lung cancers that have failed previous treatment with anti-PD-1 therapy and chemotherapy. Data from the Phase 1b/2 clinical study has been accepted for presentation at the Society for Immunotherapy of Cancer annual meeting in November.
Corvus Pharmaceuticals call volume above normal and directionally bullish » 15:2509/2109/21/21
Bullish option flow…
Bullish option flow detected in Corvus Pharmaceuticals with 31,825 calls trading, 8x expected, and implied vol increasing over 16 points to 222.80%. Oct-21 7.5 calls and Oct-21 10 calls are the most active options, with total volume in those strikes near 23,400 contracts. The Put/Call Ratio is 0.57. Earnings are expected on October 28th.
Corvus Pharmaceuticals' CPI-818 approved for Phase 1/1b trial in China » 17:0508/1608/16/21
Corvus Pharmaceuticals' CPI-818 licensee Angel Pharma announced that the Center for Drug Evaluation of the China National Medical Products Administration has accepted its IND application for the initiation of a Phase 1/1b clinical trial of its small molecule ITK inhibitor CPI-818 for treatment of relapsed/refractory T-cell lymphomas. Angel Pharma licensed the rights to CPI-818 from Corvus Pharmaceuticals for development, manufacturing and commercialization in China. Angel Pharmaceuticals announced plans to initiate the trial before the end of 2021. CPI-818 has been shown to selectively inhibit ITK without effect on related kinases. ITK is a 72 kDa protein kinase that plays an essential role in the activation, differentiation and proliferation of T-cells. Based on these properties, ITK is a promising treatment target for autoimmune diseases and for lymphoproliferative diseases such as T-cell lymphomas. Corvus is studying CPI-818 in a multi-center Phase 1/1b clinical trial in patients with several types of TCL in the U.S. and Asia. Overall, CPI-818 has been shown to be well-tolerated, and has shown anti-tumor activity in peripheral T-cell lymphomas and in cutaneous T-cell lymphomas.
Corvus Pharmaceuticals price target lowered to $5 from $10 at Cantor Fitzgerald » 07:3508/0308/03/21
Cantor Fitzgerald analyst…
Cantor Fitzgerald analyst Li Watsek lowered the firm's price target on Corvus Pharmaceuticals to $5 from $10 and keeps an Overweight rating on the shares after taking out the opportunity of mupadolimab in COVID-19 following the trial discontinuation and adding the opportunity in HPV+ head and neck cancer.
Corvus Pharmaceuticals price target lowered to $3.50 from $4 at Mizuho » 06:3708/0308/03/21
Mizuho analyst Mara…
Mizuho analyst Mara Goldstein lowered the firm's price target on Corvus Pharmaceuticals to $3.50 from $4 and keeps a Neutral rating on the shares. The Q2 earnings was as expected following the recent announcement to discontinue the mupadolimab program for the treatment of SARSCoV-2 infected patients, Goldstein tells investors in a research note. The analyst's valuation is based on potential of mupadolimab in a variety of virally-driven cancers.
|Over a quarter ago|
Corvus Pharmaceuticals price target lowered to $6 from $9.50 at H.C. Wainwright » 06:1107/1607/16/21
H.C. Wainwright analyst…
H.C. Wainwright analyst Swayampakula Ramakanth lowered the firm's price target on Corvus Pharmaceuticals to $6 from $9.50 and keeps a Buy rating on the shares. The analyst removed Covid-19 and metastatic castrate-resistant prostate cancer revenues for mupadolimab given the discontinuation of the Phase 3 study.
Fly Intel: After-Hours Movers » 18:1807/1507/15/21
AEHR, MRNA, PFDR, AOUT, MRTN, CRVS
Check out this evening's…
Corvus Pharmaceuticals trading resumes 16:3507/1507/15/21